Company Overview
Bioventus Inc. operates as a medical device company dedicated to relieving pain and addressing musculoskeletal therapies for patients in the United States and internationally. The company functions within the healthcare sector, specifically focusing on the medical devices industry, which involves the manufacturing and distribution of specialized equipment for clinical procedures. This entity employs approximately 930 individuals and maintains a market capitalization of $616.42M alongside annual revenue of $568.09M. These valuation and revenue figures indicate that Bioventus holds a mid-sized position in its niche, generating substantial revenue that supports a significant workforce while maintaining a market cap that reflects its established presence in the medical device landscape.
Financial Health
The company reported revenue of $568.09M and net income of $22.73M over the trailing twelve months, with an EBITDA of $77.64M. The significant gap between the total revenue and net income reveals a substantial cost structure where operating expenses, taxes, and interest costs consume approximately 60% of gross revenue before reaching the bottom line. Bioventus generated free cash flow of $28.15M, which provides the organization with financial flexibility to fund operations, service debt obligations, or pursue strategic investments without relying solely on external financing. The company's margins demonstrate a robust gross margin of 68.3%, indicating high pricing power or low cost of goods sold, while an operating margin of 13.8% reflects the efficiency of internal operations before interest and taxes. The profit margin of 4.0% shows the final percentage of revenue retained as earnings, suggesting that while operational efficiency is decent, significant costs related to interest or other factors impact the final bottom line. The balance sheet shows total cash of $51.24M against total debt of $311.35M, resulting in a debt-to-equity ratio of 136.29, which characterizes a leveraged balance sheet where liabilities exceed equity. Despite the high leverage, the current ratio stands at 1.70, indicating that the company holds sufficient current assets to cover short-term liabilities with a comfortable buffer of 1.7 times. Return on Equity is reported at 13.2% and Return on Assets at 5.0%, metrics that reveal how effectively management utilizes shareholder capital and total assets to generate profits, with equity being a more potent driver of returns in this capital structure.
Valuation Assessment
The stock carries a trailing P/E ratio of 27.73 and a forward P/E of 10.48, implying that the market expects earnings to grow significantly in the future to justify the high current multiple relative to expected future earnings. The price-to-book ratio is 3.33, indicating that the market values the company at a significant premium over its net asset book value, reflecting intangible assets like brand reputation or intellectual property not fully captured on the balance sheet. Alternative valuation metrics include a price-to-sales ratio of 1.09 and an EV/EBITDA of 11.86, suggesting that the company is valued slightly above its sales revenue and that its enterprise value relative to earnings before interest, taxes, depreciation, and amortization is moderate for the healthcare sector. The 52-week high is $9.98 and the 52-week low is $5.81, placing the current trading range within a wide band where the stock has exhibited notable volatility over the past year. The beta value is 0.72, meaning the stock's price volatility is lower than the broader market, suggesting it may act as a less aggressive component of a diversified portfolio compared to the overall market index.
Growth & Income
Revenue growth stands at 2.8% year-over-year, while earnings growth is listed as N/A, indicating that the data for earnings growth is not currently available or applicable for the reported period. The absence of reported earnings growth data prevents a direct comparison to revenue growth, but the modest 2.8% revenue expansion suggests steady, albeit slow, top-line expansion typical of mature medical device portfolios. Bioventus does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the company reinvests all of its net income into business operations, debt reduction, or growth initiatives rather than distributing cash to shareholders. Consequently, the overall growth and income profile for Bioventus is characterized by a focus on capital reinvestment for future expansion rather than providing immediate income through dividends, supported by a beta of 0.72 that moderates price fluctuations relative to the broader market.